Status:
UNKNOWN
Assessment of the Association Between Metabolic Associated Fatty Liver Disease (MFLD) and Biopsy Proved Cases of GN
Lead Sponsor:
Assiut University
Conditions:
Assessment of Patients With Biopsy Proven Primary Glomerulonephritis Above 18 Years of Age for MFLD Development
Eligibility:
All Genders
19-80 years
Brief Summary
Fatty liver disease is a global health concern with a prevalence of about 25% amongst United States. Its increased prevalence is attributed to increase in patients with obesity and metabolic syndrome ...
Eligibility Criteria
Inclusion
- Patients with biopsy proven primary glomerulonephritis.
- Age \>18 years
Exclusion
- Patients with e-GFR\<60ml/min/1.73m2
- Patients with secondary glomerulonephritis
- Patients with body mass index \>35 kg/m2
- Patients known to be diabetic.
- Patients known to be hypertensive.
- Patients with HCV or HBV infection either acute or chronic
- Patients with acute hepatitis whatever the aetiology
- Patients with autoimmune diseases
Key Trial Info
Start Date :
June 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06157125
Start Date
June 1 2024
End Date
July 1 2025
Last Update
December 5 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut university hospitals nephrology department
Asyut, Egypt, 71515
2
Assiut university hospitals nephrology department
Asyut, Egypt, 71515